CoTherix Inc., of South San Francisco, appointed Christine Gray-Smith chief financial officer and executive vice president.
Enhance Biotech Inc., of New York, appointed David Scales to its board.
Eximias Pharmaceutical Corp., of Berwyn, Pa., appointed Robert Gish and Yehuda Patt co-principal investigators for the pivotal Phase III trial of Thymitaq in unresectable hepatocellular carcinoma.
Gastrotech Pharma A/S, of Copenhagen, Denmark, appointed Lise Abildgaard Ryberg senior vice president of intellectual property rights, and Hans Schambye senior vice president of research and development.
Genetics Squared, of Ann Arbor, Mich., named John Freshley president and CEO.
Geospiza, of Seattle, appointed Rob Arnold president and chief operating officer.
Goodnow Capital LLC, of New York, a majority shareholder in Incara Pharmaceuticals Corp., of Research Triangle Park, N.C., appointed to Incara's board David Cavalier as chairman, and Richard Burgoon and Alan Tuchman as members.
Hudson Health Sciences Inc., of South San Francisco, elected Arie Belldegrun to its board.
Hydra Biosciences Inc., of Cambridge, Mass., said its co-founder Mark Keating was elected to the National Academy of Sciences.
Ingenium Pharmaceuticals AG, of Munich, Germany, appointed Georges Haas to its supervisory board.
Iomed Inc., of Salt Lake City, appointed James Isaacson director of design and development engineering.
Kereos, of St. Louis, added Michael Loberg to its board.
The Massachusetts Biotechnology Council, of Boston, appointed Una Ryan to its board chair position, and Geoffrey Cox, John Hennessey, Mark Leuchtenberger and Steven Richter to its board.
Merrimack Pharmaceuticals Inc., of Cambridge, Mass., appointed Gary Crocker to its board.
Metabasis Therapeutics Inc., of San Diego, appointed Daniel Burgess to its board as chairman of the audit committee.
MicroIslet Inc., of San Diego, appointed Daniel Salomon senior research fellow, and Ronnda Bartel executive director of biological research.
NaPro BioTherapeutics Inc., of Boulder, Colo., appointed Paul Bunn chairman of the oncology scientific advisory board.
NeoPharm Inc., of Lake Forest, Ill., promoted Imran Ahmad to executive vice president and chief scientific officer.
Northeastern University in Boston added Alexandros Makriyannis to its faculty as part of a five-year, $75 million plan to strengthen research and graduate programs in sciences and engineering.
Odyssey Pharmaceuticals, of East Hanover, N.J., appointed Andy Jordan senior vice president, chief financial officer and a member of the executive committee.
Peninsula Pharmaceuticals Inc., of Alameda, Calif., elected David MacCallum to its board.
Serologicals Corp., of Atlanta, appointed Dennis Harris chief scientific officer and vice president of research and development and business development.
Sonus Pharmaceuticals Inc., of Bothell, Wash., appointed Michelle Burris to its board.
SurroMed Inc., of Menlo Park, Calif., promoted Christopher Becker to vice president of chemistry, and William Leschensky to vice president of intellectual property.
The Technology Council of Maryland, of Rockville, Md., appointed Neil Campbell to its board.
Third Wave Technologies Inc., of Madison, Wis., appointed its co-founder Lance Fors executive chairman, and John Puisis CEO and board member.
TransForm Pharmaceuticals Inc., of Lexington, Mass., appointed Paul Goldenheim president and a member of its board.
UBS Warburg, of New York, appointed as health care analysts for U.S. equity research Carl Seiden, to cover major pharmaceuticals, and David Molowa, to cover biotechnology.
Ventaira Pharmaceuticals Inc., of Columbus, Ohio, appointed Gregory Frank to its board.
Versant Ventures, of Menlo Park, Calif., appointed Bradley Bolzon managing director.
Vertex Pharmaceuticals Inc., of Cambridge, Mass., re-elected Joshua Boger, Charles Sanders and Elaine Ullian, and appointed Eve Slater and John Niblack to its board.
Wilex AG, of Munich, Germany, appointed Niels Ackerman chief financial officer.